Improved anticancer effects of epigallocatechin gallate using RGD-containing nanostructured lipid carriers

References

• Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 2013;36:715–718.
   PubMed Web of Science ®Google Scholar
• Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315–318.
   PubMed Web of Science ®Google Scholar
• Vella N, Aiello M, Russo AE, et al. ‘Genetic profiling’and ovarian cancer therapy (review). Molecular Med Rep. 2011;4:771–777.
   PubMed Web of Science ®Google Scholar
• Barghi S, Amiri M, Hajipour H, et al. The effect of dietary constituents on regulation of epigenetic changes in cancer. J Babol Univ Med Sci. 2017;19:63–71.
   Google Scholar
• Wang P, Heber D, Henning SM. Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer. 2012;64:580–587.
   PubMed Web of Science ®Google Scholar
• Wang CC, Xu H, Man GCW, et al. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis. 2013;16:59–69.
   PubMed Web of Science ®Google Scholar
• Shuntaro T, Keisuke H, Motofumi K, et al. Green tea polyphenol EGCG induces lipid-raft clustering and apoptotic cell death by activating protein kinase Cdelta and acid sphingomyelinase through a 67 kDa laminin receptor in multiple myeloma cells. Biochem J. 2012;443:525–534.
   PubMed Web of Science ®Google Scholar
• Hajipour H, Hamishehkar H, Raeisi S, et al. Epigallocatechin-3-gallate induces apoptosis through up-regulation of bax and down-regulation of Bcl-2 in prostate cancer cell line. Int J Med Lab. 2016;3:262–269.
   Google Scholar
• Jodoin J, Demeule M, Béliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochimica Et Biophysica Acta (BBA)-Molecular Cell Res. 2002;1542:149–159.
   PubMed Web of Science ®Google Scholar
• Cai Y, Anavy ND, Chow HS. Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats. Drug Metab Dispos. 2002;30:1246–1249.
   PubMed Web of Science ®Google Scholar
• Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81:230S–242S.
   PubMed Web of Science ®Google Scholar
• Rocha S, Generalov R, Pereira MC, et al. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine. 2011;6:79–87.
   PubMed Web of Science ®Google Scholar
• Fasihi-Ramandi M, Ghobadi-Ghadikolaee H, Ahmadi-Renani S, et al. Vibrio cholerae lipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype. Artif Cells Nanomed Biotechnol 2017 [Feb 28]; [6 p.]. DOI:https://doi.org/10.1080/21691401.2017.1290646
   Google Scholar
• Bagdeli S, Rezayan AH, Taheri RA, et al. FRET-based immunoassay using CdTe and AuNPs for the detection of OmpW antigen of Vibrio cholerae. J Lumin. 2017;192:932–939.
   Web of Science ®Google Scholar
• Tamjidi F, Shahedi M, Varshosaz J, et al. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innova Food Sci Emerg Technol. 2013;19:29–43.
   Web of Science ®Google Scholar
• Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert Opin Drug Deliv 2009; 6:165–176.
   PubMed Web of Science ®Google Scholar
• Pearce TR, Shroff K, Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater Weinheim. 2012;24:3803–3822.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD-and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14:972–981.
   PubMed Web of Science ®Google Scholar
• Van de Walle GR, Peters ST, VanderVen BC, et al. Equine herpesvirus 1 entry via endocytosis is facilitated by αV integrins and an RSD motif in glycoprotein D. J Virol. 2008;82:11859–11868.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
   PubMed Web of Science ®Google Scholar
• Marelli UK, Rechenmacher F, Sobahi TRA, et al. Tumor targeting via integrin ligands. Front Oncol. 2013;3:222.
   PubMedGoogle Scholar
• Cao Y, Zhou Y, Zhuang Q, et al. Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer. Int J Clin Exp Med. 2015;8:12182.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. Ca Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, Bao Y, et al. Novel reduction-sensitive pullulan-based micelles with good hemocompatibility for efficient intracellular doxorubicin delivery. RSC Adv. 2014;4:60064–60074.
   Web of Science ®Google Scholar
• Ngamcherdtrakul W, Morry J, Gu S, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater. 2015;25:2646–2659.
   PubMed Web of Science ®Google Scholar
• Martins S, Costa-Lima S, Carneiro T, et al. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430:216–227.
   PubMed Web of Science ®Google Scholar
• Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerf. 2013;110:313–320.
   PubMed Web of Science ®Google Scholar
• Eskandani M, Nazemiyeh H. Self-reporter shikonin-act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation. Eur J Pharm Sci. 2014;59:49–57.
   PubMed Web of Science ®Google Scholar
• Bauer K, Mierke C, Behrens J. Expression profiling reveals genes associated with transendothelial migration of tumor cells: a functional role for alphavbeta3 integrin. Int J Cancer. 2007;121:1910–1918.
   PubMed Web of Science ®Google Scholar
• Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–636.
   PubMed Web of Science ®Google Scholar
• Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci. 2001;98:1853–1858.
   PubMed Web of Science ®Google Scholar
• Huveneers S, van den Bout I, Sonneveld P, et al. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src. Cancer Res. 2007;67:2693–2700.
   PubMed Web of Science ®Google Scholar
• Du J, Lu W-L, Ying X, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood − brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 2009;6:905–917.
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149–168.
   PubMed Web of Science ®Google Scholar
• Farabegoli F, Papi A, Bartolini G, et al. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine. 2010;17:356–362.
   PubMed Web of Science ®Google Scholar
• Pandey R, Ahmad Z, Sharma S, et al. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm. 2005;301:268–276.
   PubMed Web of Science ®Google Scholar
• Kakran M, Sahoo N, Li L. Dissolution enhancement of quercetin through nanofabrication, complexation, and solid dispersion. Colloids Surf B Biointerfaces. 2011;88:121–130.
   PubMed Web of Science ®Google Scholar
• Thakur VS, Amin AR, Paul RK, et al. p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Lett. 2010;296:225–232.
   PubMed Web of Science ®Google Scholar
• Stearns ME, Amatangelo MD, Varma D, et al. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol. 2010;177:3169–3179.
   PubMed Web of Science ®Google Scholar
• Luo T, Wang J, Yin Y, et al. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 2010;12:R8.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Vazquez-Martin A, Colomer R, et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells. BMC Cancer. 2007;7:80.
   PubMed Web of Science ®Google Scholar
• Zu Y, Yuan S, Zhao X, et al. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles. Yao Xue Xue Bao = Acta Pharmaceutica Sinica 2009;44:525–531.
   PubMedGoogle Scholar
• Siddiqui IA, Bharali DJ, Nihal M, et al. Excellent anti-proliferative and pro-apoptotic effects of (−)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomed Nanotechnol Biol Med. 2014;10:1619–1626.
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Prasad P, Leung M, et al. A novel solid lipid nanoparticle formulation for active targeting to tumor αvβ3 integrin receptors reveals cyclic RGD as a double‐edged sword. Adv Healthcare Mater. 2012;1:600–608.
   Web of Science ®Google Scholar